Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) rose 3.1% on Tuesday . The company traded as high as $13.80 and last traded at $13.80. Approximately 8,827 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 41,049 shares. The stock had previously closed at $13.39.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upped their price objective on Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd.
Read Our Latest Analysis on Greenwich LifeSciences
Greenwich LifeSciences Stock Up 3.1 %
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). Equities research analysts forecast that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Greenwich LifeSciences news, CEO Snehal Patel purchased 5,500 shares of the business’s stock in a transaction on Monday, August 5th. The stock was acquired at an average price of $13.18 per share, with a total value of $72,490.00. Following the acquisition, the chief executive officer now directly owns 5,532,602 shares of the company’s stock, valued at $72,919,694.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have acquired 8,800 shares of company stock valued at $120,665. 52.86% of the stock is owned by insiders.
Hedge Funds Weigh In On Greenwich LifeSciences
A number of large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences in the 2nd quarter valued at $264,000. Rhumbline Advisers bought a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $117,000. Finally, Vanguard Group Inc. grew its stake in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after acquiring an additional 1,420 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Stories
- Five stocks we like better than Greenwich LifeSciences
- Consumer Staples Stocks, Explained
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is the Nasdaq? Complete Overview with History
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Insider Trades May Not Tell You What You Think
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.